PMID- 37016186
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230616
IS  - 2366-1089 (Electronic)
IS  - 2366-1070 (Print)
IS  - 2366-1089 (Linking)
VI  - 11
IP  - 2
DP  - 2023 Jun
TI  - Real-World Outcomes Following First-Line Treatment in Patients with Advanced 
      Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received 
      Maintenance Therapy or Active Surveillance.
PG  - 245-261
LID - 10.1007/s40487-023-00227-6 [doi]
AB  - INTRODUCTION: We evaluated real-world outcomes in patients with advanced ovarian 
      cancer (AOC) based on their cumulative risk profile and maintenance therapy (MT) 
      status following first-line (1L) treatment. METHODS: This retrospective 
      observational study of a nationwide electronic health record-derived 
      de-identified database included adult patients diagnosed with stage III/IV OC 
      from January 1, 2011 to February 28, 2021, who received 1L therapy and had 
      >/= 12 weeks of follow-up after the index date (end of 1L therapy). Patients were 
      grouped according to whether they received MT or active surveillance (AS) 
      following 1L treatment and by the cumulative number of risk factors (RF) present 
      (stage IV disease; no surgery/treated with neoadjuvant therapy and interval 
      debulking surgery; had postoperative visible residual disease; and had BRCA 
      wild-type disease/unknown BRCA status). Time to next treatment (TTNT) and overall 
      survival (OS) were assessed with a cloning and inverse probability of censoring 
      (IPC)-weighted Kaplan-Meier method. RESULTS: Among 1920 patients, 22.2% received 
      MT and 77.8% received AS. Median IPC-weighted TTNT and OS were 13.3 months 
      (95% CI 11.7-15.8) and 39.1 months (95% CI 32.5-48.6) in the MT cohort, 
      respectively, and 8.6 months (95% CI 8.0-9.5) and 38.4 months (95% CI 36.4-41.0) 
      in the AS cohort, respectively. Almost all patients had >/= 1 RF (MT 95.3%; AS 
      96.7%). Median IPC-weighted TTNT was shorter among patients with more RF in both 
      cohorts (MT: 1 RF, 19.3 months, 95% CI 13.5-37.8; 2 RF, 17.2 months, 95% CI 
      12.8-20.2; 3 RF, 11.0 months, 95% CI 8.2-13.8; 4 RF, 7.0 months, 95% CI 6.2-8.8; 
      AS: 1 RF, 17.7 months, 95% CI 13.5-22.3; 2 RF, 10.2 months, 95% CI 9.1-11.5; 
      3 RF, 6.5 months, 95% CI 5.8-7.4; 4 RF, 4.1 months, 95% CI 3.5-4.5). CONCLUSION: 
      Regardless of RF number, MT was associated with longer TTNT in real-world 
      patients with AOC.
CI  - (c) 2023. The Author(s).
FAU - Chase, Dana
AU  - Chase D
AD  - David Geffen School of Medicine at University of California Los Angeles, Los 
      Angeles, CA, USA.
FAU - Perhanidis, Jessica
AU  - Perhanidis J
AUID- ORCID: 0000-0001-6943-8500
AD  - GSK, 1000 Winter Street, Waltham, MA, 02451, USA. jessica.x.perhanidis@gsk.com.
FAU - Gupta, Divya
AU  - Gupta D
AD  - Mersana Therapeutics, Inc, Cambridge, MA, USA.
FAU - Kalilani, Linda
AU  - Kalilani L
AD  - GSK, Durham, NC, USA.
FAU - Golembesky, Amanda
AU  - Golembesky A
AD  - GSK, Durham, NC, USA.
FAU - Gonzalez-Martin, Antonio
AU  - Gonzalez-Martin A
AD  - Medical Oncology Department, Cancer Center Clinica Universidad de Navarra, 
      Madrid, Spain.
AD  - Program in Solid Tumours, CIMA, Pamplona, Spain.
AD  - Grupo Espanol de Investigacion en Cancer de Ovario (GEICO), Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20230404
PL  - New Zealand
TA  - Oncol Ther
JT  - Oncology and therapy
JID - 101677510
PMC - PMC10260707
OTO - NOTNLM
OT  - Electronic health records
OT  - Maintenance therapy
OT  - Ovarian cancer
OT  - Risk factors
COIS- Dana Chase reports speakers' bureau fees and/or advisory roles from, AstraZeneca, 
      Clovis, Genentech/Roche, and GSK and consulting fees from GSK, AstraZeneca, 
      Clovis, and Genentech/Roche. Jessica Perhanidis is a current employee of GSK and 
      reports financial interest (stock) in Boston Scientific and GSK. Linda Kalilani 
      and Amanda Golembesky are current employees of GSK. Divya Gupta was an employee 
      of GSK at the time the analysis was conducted, and is currently affiliated 
      with Mersana Therapeutics, Inc, Cambridge, MA, USA. Antonio Gonzalez-Martin 
      reports honoraria as advisor from Alkermes, Amgen, AstraZeneca, Clovis Oncology, 
      Genmab, GSK, HederaDx, ImmunoGen, Merck Sharp & Dohme, MacroGenics, Novartis, 
      Oncoinvent, Pfizer/Merck, PharmaMar, Roche, Sotio, Sutro; honoraria as speaker 
      for AstraZeneca, Clovis, GSK, PharmaMar, Roche; institutional funding (GEICO) for 
      clinical research from Roche and GSK; and non-remunerated activities as chair in 
      GEICO and ENGOT (for the period 2018-2020).
EDAT- 2023/04/05 06:00
MHDA- 2023/04/05 06:01
PMCR- 2023/04/04
CRDT- 2023/04/04 23:30
PHST- 2023/01/19 00:00 [received]
PHST- 2023/03/09 00:00 [accepted]
PHST- 2023/04/05 06:01 [medline]
PHST- 2023/04/05 06:00 [pubmed]
PHST- 2023/04/04 23:30 [entrez]
PHST- 2023/04/04 00:00 [pmc-release]
AID - 10.1007/s40487-023-00227-6 [pii]
AID - 227 [pii]
AID - 10.1007/s40487-023-00227-6 [doi]
PST - ppublish
SO  - Oncol Ther. 2023 Jun;11(2):245-261. doi: 10.1007/s40487-023-00227-6. Epub 2023 
      Apr 4.